AstraZeneca on Wednesday earned Food and Drug Administration approval for its asthma drug Fasenra.
Here are three things to know.
1. Fasenra is respiratory biologic used as a maintenance treatment for patients 12 years and older with severe asthma.
2. The drug is administered as a fixed-dose subcutaneous injection once a month for the first three doses, and then once every two months.
3. The first year of treatment will cost $38,000, with following annual treatment costs ranging from $28,000 to $33,000, depending on how many doses the patient receives, according to Reuters.
More articles on supply chain:
Hospitals face critical saline bag shortage: 6 things to know
Amazon: We will use pharmacy licenses in Indiana, Tennessee to sell medical devices, not medication
Prime Healthcare taps HealthTrust for GPO services